Drug companies AbbVie and Genentech will start selling medications at lower prices through the White House’s "TrumpRx" website.

Foundayo is now available for adult patients with obesity and weight-related comorbidities to reduce excess body weight and maintain reduction.

Low food access (LFA) is associated with increased comorbidities and postoperative complications for women undergoing mastectomy.

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

Current BMI classification may overestimate the prevalence of underweight, overweight, and obesity among the general population.

Multiple manufacturers receive FDA approval for generic dapagliflozin to treat type 2 diabetes and lower heart failure risks in high-risk T2D patients.

For adults aged 65 years and older, the risk for incident AD is lower for those who receive a high versus standard dose of IIV.

Researchers identify an optimal visceral adipose tissue range of 46.5-116.6 cm² to minimize the combined risk of diabetes and osteoporosis.

A study of 132,000 children finds that high BMI in mid- to late childhood is the strongest predictor of early pubertal onset.

Ixekizumab (IXE) plus tirzepatide shows significant benefits for outcomes in PsA vs IXE alone in adults with overweight or obesity.

The AHA released new nutrition guidance recommending plant-based proteins like beans, lentils and nuts instead of red and processed meats.

Intravitreal conbercept (IVC) loading injections alone leads to significant improvements in the microvasculature in proliferative DR.